Exelixis targets $5B Zanza sales by 2033 with multiple pivotal trials in progress
CEO Mike Morrissey highlighted significant momentum in 2024, emphasizing the company's goal of achieving $3 billion in annual cabozantinib (Cabo) revenue by 2030 and $5 billion for zanzalintinib ...